Literature DB >> 31692743

Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial.

Zulfu Sertkaya1, Fatih Ozkaya2.   

Abstract

OBJECTIVE: Nocebo effect is known in patients refered to side effects of drugs that cause more side effects than expected. Side effects on sexual function have been reported in about 60% of patients using silodosin. To investigate whether there was nocebo effect of silodosin in the side effects on sexual function.
MATERIALS AND METHODS: Between May 2014 and March 2017, 129 moderate-to-severe LUTS patients were included in the study. For the patients, PSA (ng/mL), prostate volume (cc), uroflowmetry test IIEF-15 and IPSS questionnaires were filled at the time of before and after treatment. Patients were divided into two groups, referred to as side effects that was mentioned and not mentioned. After 3 months control, all patients were asked whether they had sexual side effects. It was analyzed whether there was significantly differences between two groups.
RESULTS: The groups were compared in terms of the frequency of androgenic side effects, low semen volume was 40.9% in Group 1 and 22.2% in Group 2 (p=0.04). Anejaculation rates were 6% and 4%, respectively (p=0.12); loss of libido and erectile dysfunction were observed in one patient in both groups (p=0.42). There was no statistically significant difference between the groups for anejaculation, decreased libido and erectile dysfunction. 9 patients (7%) who left medication due to side effects were excluded from the study.
CONCLUSION: In patients, mentioned about the sexual side effects, low semen volume was seen more frequantly, but anejaculation, decreased libido and erectile dysfunction were same. Therefore, be informed about the side effects before treatment is a matter of debate. ©Copyright 2019 by the Atatürk University School of Medicine - Available online at www.eurasianjmed.com.

Entities:  

Keywords:  Nocebo effect; silodosin; urology

Year:  2019        PMID: 31692743      PMCID: PMC6812912          DOI: 10.5152/eurasianjmed.2019.19139

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  19 in total

Review 1.  How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?

Authors:  Raymond A Costabile; William D Steers
Journal:  J Sex Med       Date:  2006-07       Impact factor: 3.802

Review 2.  New insights into the placebo and nocebo responses.

Authors:  Paul Enck; Fabrizio Benedetti; Manfred Schedlowski
Journal:  Neuron       Date:  2008-07-31       Impact factor: 17.173

3.  Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.

Authors:  Teruhiko Yokoyama; Ryoei Hara; Kazuhiko Fukumoto; Tomohiro Fujii; Yoshimasa Jo; Yoshiyuki Miyaji; Atsushi Nagai; Atsushi Sone
Journal:  Int J Urol       Date:  2011-01-27       Impact factor: 3.369

Review 4.  The nocebo phenomenon: concept, evidence, and implications for public health.

Authors:  R A Hahn
Journal:  Prev Med       Date:  1997 Sep-Oct       Impact factor: 4.018

Review 5.  Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.

Authors:  Mauro Gacci; Vincenzo Ficarra; Arcangelo Sebastianelli; Giovanni Corona; Sergio Serni; Shahrokh F Shariat; Mario Maggi; Filiberto Zattoni; Marco Carini; Giacomo Novara
Journal:  J Sex Med       Date:  2014-04-07       Impact factor: 3.802

Review 6.  Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Authors:  Raymond C Rosen; Francois Giuliano; Culley C Carson
Journal:  Eur Urol       Date:  2005-01-05       Impact factor: 20.096

7.  Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.

Authors:  Christopher R Chapple; Francesco Montorsi; Teuvo L J Tammela; Manfred Wirth; Evert Koldewijn; Eldiberto Fernández Fernández
Journal:  Eur Urol       Date:  2010-11-10       Impact factor: 20.096

8.  Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate.

Authors:  P D Walden; M M Durkin; H Lepor; J M Wetzel; C Gluchowski; E L Gustafson
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

Review 9.  Nocebo phenomena in medicine: their relevance in everyday clinical practice.

Authors:  Winfried Häuser; Ernil Hansen; Paul Enck
Journal:  Dtsch Arztebl Int       Date:  2012-06-29       Impact factor: 5.594

10.  Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration.

Authors:  K Kobayashi; N Masumori; R Kato; S Hisasue; R Furuya; T Tsukamoto
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

View more
  1 in total

1.  Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity.

Authors:  Abdullah Gul; Soner Coban; Ali Riza Turkoglu; Muhammet Guzelsoy; Murat Ozturk; Nazim Abdulkadir Kankilic
Journal:  Prostate Int       Date:  2020-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.